Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05774899 · ClinicalTrials.gov registry record · Phase 1
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
A Phase 1 study of Adenoid Cystic Carcinoma and Metastatic Adenoid Cystic Carcinoma, sponsored by Glenn J. Hanna.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT05774899 is a Phase 1 study of Adenoid Cystic Carcinoma and Metastatic Adenoid Cystic Carcinoma that is actively recruiting participants, run by Glenn J. Hanna. The registered enrollment target is 32 participants, below the 126-participant average among 16 other Adenoid Cystic Carcinoma trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05774899, a Phase 1 study of Adenoid Cystic Carcinoma and Metastatic Adenoid Cystic Carcinoma, is actively recruiting participants, sponsored by Glenn J. Hanna.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to treat patients with NOTCH active advanced adenoid cystic carcinoma (ACC) tumors with a combination or two different oral medications to slow tumor growth and improve survival outcomes. The names of the study drugs involved in this study are: * CB-103 (an oral NOTCH pathway inhibitor) * Abemaciclib (CDK4/6 inhibitor) * Lenvatinib (a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI))
Conditions Studied
Interventions
- DRUG Abemaciclib
- DRUG Lenvatinib
- DRUG CB-103
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05774899
The ClinicalTrials.gov registry entry for NCT05774899 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 126-participant average among 16 other Adenoid Cystic Carcinoma trials with a reported enrollment target (75% lower). The listed sponsor is Glenn J. Hanna, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Adenoid Cystic Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Abemaciclib is the first listed.
NCT05774899 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05774899 about?
NCT05774899 is a clinical study titled "CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC". The goal of this study is to treat patients with NOTCH active advanced adenoid cystic carcinoma (ACC) tumors with a combination or two different oral medications to slow tumor growth and improve survival outcomes. The names of the study drugs involved in this study are: * CB-103 (an oral NOTCH pat...
What is the current status of trial NCT05774899?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2023-06-01. Estimated completion is 2027-06-01.
What conditions does trial NCT05774899 study?
This clinical trial studies the following conditions: Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma.
What interventions are being tested in trial NCT05774899?
The interventions under investigation include: Abemaciclib (DRUG), Lenvatinib (DRUG), CB-103 (DRUG).
Who is sponsoring clinical trial NCT05774899?
This trial is sponsored by Glenn J. Hanna, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05774899 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenoid Cystic Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
RECRUITING · Phase 1
-
Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
RECRUITING · Phase 1
-
A Study of XMT-1660 in Participants With Solid Tumors
RECRUITING · Phase 1
-
AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Adenoid Cystic Carcinoma
All registered trials for this condition
Metastatic Adenoid Cystic Carcinoma
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.